Clinical Trials Sponsored by Bill McGhee

Total 2287 results

Aga Khan University
Bill and Melinda Gates Foundation

Completed

Implementation at Scale and Evaluation of KMC (KMC)

Newborn Morbidity

Pakistan
Vir Biotechnology, Inc.
Bill and Melinda Gates Foundation

Completed

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

HIV I Infection

United States
University of Washington
Bill and Melinda Gates Foundation

Terminated

Treatment for COVID-19 in High-Risk Adult Outpatients

COVID-19 | SARS-CoV-2

United States
University of Minnesota
Bill and Melinda Gates Foundation

Completed

Losartan for Patients With COVID-19 Requiring Hospitalization

Acute Respiratory Distress Syndrome | Corona Virus Infection | SARS-CoV Infection

United States
Aga Khan University
Bill and Melinda Gates Foundation

Completed

Community Mobilization and Incentivization for Childhood Diarrhea and Pneumonia (CoMIC)

Childhood Diarrhea | Childhood Pneumonia | Community Mobilisation | Sanitation and Hygiene | Community Incentives

Pakistan
Aga Khan University
Bill and Melinda Gates Foundation

Unknown

Implementation Research of Kangaroo Mother Care in Rural Pakistan. (KMC)

Low-Birth-Weight Infant

Pakistan
University of Washington
Bill and Melinda Gates Foundation

Completed

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples (Partners PrEP)

HIV Infections | HIV-1 Infections

Kenya, Uganda
Massachusetts General Hospital
Bill and Melinda Gates Foundation

Enrolling by invitation

OCT Guided Trans Nasal Imaging of the Small Intestine in Adults

Environmental Enteric Dysfunction

United States
University of Washington
Bill and Melinda Gates Foundation

Completed

A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women (INSIGHT)

HIV Infections

Kenya, Malawi, South Africa, Swaziland, Uganda, Zambia, Zimbabwe
Aga Khan University
Bill and Melinda Gates Foundation

Completed

Impact of Pulse Oximetry on Hospital Referral Acceptance in Children Under 5 With Severe Pneumonia

Hypoxemia | Severe Pneumonia

Pakistan
University of Washington
Bill and Melinda Gates Foundation

Completed

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

COVID-19 | Corona Virus Infection | SARS-CoV-2 | SARS (Severe Acute Respiratory Syndrome)

United States
Imperial College London
Bill and Melinda Gates Foundation

Completed

Optimising DNA Vaccinations in Healthy Volunteers (DNAVAC001)

HIV-1-infection
University of Washington
Bill and Melinda Gates Foundation

Completed

Delivery Optimization for Antiretroviral Therapy (The DO ART Study) (DO ART)

HIV | ART

South Africa, Uganda
University of Nottingham
Bill and Melinda Gates Foundation

Completed

Gestational Age Assessment Tool (GestATion)

Premature Birth | Immature Newborn

United Kingdom
Johns Hopkins University
Bill and Melinda Gates Foundation

Completed

Partnership for Rapid Elimination of Trachoma (PRET)

Trachoma

United States, United Kingdom
Virginia Commonwealth University
Bill and Melinda Gates Foundation

Completed

Pilot Study of Oral Probiotic Bacteria Supplementation to Reduce Chronic Immune Activation in HIV-infected Malian Women

HIV

Mali
University of Oxford
Bill and Melinda Gates Foundation

Unknown

Risk Factors for Severe Morbidity and Mortality in Mothers and Neonates (KIPMAT)

Maternal and Newborn Health

Kenya
Southwest Oncology Group
Bill and Melinda Gates Foundation

Completed

S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)

Helicobacter Pylori Infection

Chile, Colombia, Costa Rica, Honduras, Mexico, Nicaragua
University of Pennsylvania
Bill and Melinda Gates Foundation

Completed

Two-Dose Methotrexate for Ectopic Pregnancy

Ectopic Pregnancy

United States
Immtech Pharmaceuticals, Inc
Bill and Melinda Gates Foundation

Completed

A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

Trypanosomiasis, African

Angola, Congo
Albert Schweitzer Hospital
Bill and Melinda Gates Foundation

Terminated

Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children

Malaria

Gabon
Bial - Portela C S.A.

Active, not recruiting

OpicApone Sleep dISorder (OASIS)

Parkinson Disease

Portugal
Oak Hill Bio Ltd

Terminated

Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

Intraventricular Hemorrhage | Bronchopulmonary Dysplasia | Chronic Lung Disease of Prematurity | Retinopathy of Prematurity (ROP)

United States, Italy, United Kingdom
Bial - Portela C S.A.

Terminated

Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058

Pulmonary Arterial Hypertension
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 (ADME)

Pulmonary Arterial Hypertension

Netherlands
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy
Bial - Portela C S.A.

Completed

Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Healthy

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Bial - Portela C S.A.

Completed

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

Parkinson's Disease

United Kingdom
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Parkinson's Disease

Romania, Ukraine
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers

Parkinson's Disease
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

Epilepsy
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Parkinson's Disease

France, Russian Federation
Bial - Portela C S.A.

Completed

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

Epilepsy

Clinical Trials Sponsored by Bill McGhee

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations